The U.S. Preventive Services Task Force for the first time has issued recommendations on genetic counseling and DNA-based testing for a disease.
The U.S. Preventive Services Task Force for the first time has issued recommendations on genetic counseling and DNA-based testing for a disease.
In the Sept. 6 issue of the Annals of Internal Medicine, the USPSTF recommended against routine genetic counseling and DNA testing to detect the presence of BRCA1 and BRCA2 gene mutations that may be associated with breast or ovarian cancers. Women lacking a family history of either breast or ovarian cancer and unlikely to test positive for the mutations should not be referred for testing, according to the report.
The task force did say that physicians should suggest counseling and testing for women with specific family histories that put them at risk. The report found evidence in the scientific literature that women with BRCA1 and BRCA2 mutations can reduce their risk of developing breast or ovarian cancer by mastectomy or oophorectomy. Women may also choose to undergo intensive screening by frequent clinical breast exams and mammography or preventive chemotherapy, but the benefits remain uncertain.
Only about 2% of women have family history that put them at risk for BRCA mutations. Even among women with these mutations, not everyone will actually develop breast or ovarian cancer, the report said.
Members of the task force expressed concern about potential harms involved with genetic testing, including false positives, unnecessary surgery, and job or insurance discrimination. This type of testing can cost thousands of dollars, and insurance coverage varies.
But for the few women with specific family history that puts them at risk, counseling and testing could offer reassurance.
"A woman who gains an understanding of the risk she faces may feel less anxious and have a sense of better control of her future," said task force chair Dr. Ned Calonge. "If the DNA test result is positive, the patient and her physician should take a shared decision-making approach in deciding which preventive measures are appropriate."
For more information from the Diagnostic Imaging archives:
U.K. study strengthens case in support of breast MR screening
Yearly mammograms prove insufficient for BRCA carriers
Genetic testing points to earlier diagnosis in breast and ovarian cancer
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.